<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03657797</url>
  </required_header>
  <id_info>
    <org_study_id>NCX-470-17001</org_study_id>
    <nct_id>NCT03657797</nct_id>
  </id_info>
  <brief_title>Phase 2 Dose-Response Study Evaluating the Safety and Efficacy of NCX 470 vs Latanoprost in Subjects With Open-Angle Glaucoma or Ocular Hypertension</brief_title>
  <official_title>A Phase 2, Randomized, Multicenter, Masked, Parrallel-Group, Dose-Response Study Evaluating the Safety and Efficacy of NCX 470 (3 Doses: 0.021%, 0.042%, and 0.065%) vs. Latanoprost 0.005% in Subjects With Open-Angle Glaucoma or Ocular Hypertension</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nicox Ophthalmics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Nicox Ophthalmics, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this clinical study is to evaluate the safety and efficacy of NCX 470
      ophthalmic solution in lowering intraocular pressure (IOP) in patients with ocular
      hypertension or open-angle glaucoma. Three different concentrations of NCX 470 ophthalmic
      solution (0.021%, 0.042%, and 0.065%) will be compared to latanoprost 0.005% ophthalmic
      solution.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 1, 2018</start_date>
  <completion_date type="Actual">August 23, 2019</completion_date>
  <primary_completion_date type="Actual">August 23, 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Reduction from baseline in mean diurnal IOP at the Week 4 Visit in the study eye</measure>
    <time_frame>4 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of subjects with adverse events as a measure of safety and tolerability</measure>
    <time_frame>4 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">656</enrollment>
  <condition>Glaucoma, Open-Angle</condition>
  <condition>Hypertension, Ocular</condition>
  <arm_group>
    <arm_group_label>NCX 470 0.021%</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>NCX 470 Ophthalmic Solution, 0.021% dosed once daily for 4 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>NCX 470 0.042%</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>NCX 470 Ophthalmic Solution, 0.042% dosed once daily for 4 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>NCX 470 0.065%</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>NCX 470 Ophthalmic Solution, 0.065% dosed once daily for 4 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Latanoprost 0.005%</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Latanoprost Ophthalmic Solution, 0.005% dosed once daily for 4 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>NCX 470</intervention_name>
    <description>NCX 470 Ophthalmic Solution</description>
    <arm_group_label>NCX 470 0.021%</arm_group_label>
    <arm_group_label>NCX 470 0.042%</arm_group_label>
    <arm_group_label>NCX 470 0.065%</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Latanoprost 0.005%</intervention_name>
    <description>Latanoprost 0.005% Ophthalmic Solution</description>
    <arm_group_label>Latanoprost 0.005%</arm_group_label>
    <other_name>Latanoprost</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of open-angle glaucoma or ocular hypertension in both eyes

          -  Qualifying IOP at 3 time points throughout the day at 2 visits following washout of
             IOP-lowering medication, if applicable

          -  Qualifying best-corrected visual acuity (BCVA) using the Early Treatment of Diabetic
             Retinopathy Study (ETDRS) protocol in each eye

          -  Ability to provide informed consent and follow study instructions

        Exclusion Criteria:

          -  Pigmentary or pseudoexfoliative glaucoma

          -  Narrow anterior chamber angles or disqualifying corneal thickness in either eye

          -  Clinically significant ocular disease in either eye

          -  Previous complicated surgery or certain types of glaucoma surgery in either eye

          -  Incisional ocular surgery or severe trauma in either eye within the past 6 months

          -  Uncontrolled systemic disease
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tomas Navratil, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Nicox Ophthalmics, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Texan Eye</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78731</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>August 31, 2018</study_first_submitted>
  <study_first_submitted_qc>August 31, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">September 5, 2018</study_first_posted>
  <last_update_submitted>January 10, 2020</last_update_submitted>
  <last_update_submitted_qc>January 10, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 13, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glaucoma</mesh_term>
    <mesh_term>Glaucoma, Open-Angle</mesh_term>
    <mesh_term>Ocular Hypertension</mesh_term>
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Latanoprost</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

